Nosocomial infection is a serious diagnosis and the increase in the incidence of resistant bacterias significantly affects the mortality and morbidity of patients. Developed and new antibiotics are usually not recommended for early childhood or we have insufficient experience with them.
One of the novel antibiotic is Ceftazidime/avibactam, containing broad-spectrum cephalosporin III. generation ceftazidime and the non-betalactam β-lactamase inhibitor avibactam. The use of this antibiotic in Gram-negative nosocomial sepsis caused by Klebsiella pneumoniae in the premature neonate is presented.
Indication of this antibiotic led to the management of sepsis and there were no complications. The use of the antibiotic Ceftazidime/avibactam in severe infections is considered possible in pediatrics, including the category of immature newborns.